Conflict of interest: GN was supported with scholarships from the European Stroke Organization and the Hellenic Society of Atherosclerosis. VP was supported with scholarships from the European Stroke Organization and the Hellenic Society of Atherosclerosis. AB and KM have no disclosures. PM has received speaker honoraria from Bayer and Boehringer Ingelheim and honoraria from scientific advisory boards for Bayer, Pfizer and Boehringer Ingelheim. He serves on the editorial board of the International Journal of Stroke.
Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials
Article first published online: 29 DEC 2013
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization
International Journal of Stroke
Volume 9, Issue 4, pages 489–493, June 2014
How to Cite
Ntaios, G., Papavasileiou, V., Bargiota, A., Makaritsis, K. and Michel, P. (2014), Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials. International Journal of Stroke, 9: 489–493. doi: 10.1111/ijs.12225
- Issue published online: 5 MAY 2014
- Article first published online: 29 DEC 2013
- Manuscript Accepted: 14 OCT 2013
- Manuscript Received: 18 JUN 2013
- acute stroke;
- functional outcome;
- intravenous insulin;
- poststroke hyperglycemia
Poststroke hyperglycemia has been associated with unfavorable outcome. Several trials investigated the use of intravenous insulin to control hyperglycemia in acute stroke. This meta-analysis summarizes all available evidence from randomized controlled trials in order to assess its efficacy and safety.
We searched PubMed until 15/02/2013 for randomized clinical trials using the following search items: ‘intravenous insulin’ or ‘hyperglycemia’, and ‘stroke’. Eligible studies had to be randomized controlled trials of intravenous insulin in hyperglycemic patients with acute stroke. Analysis was performed on intention-to-treat basis using the Peto fixed-effects method. The efficacy outcomes were mortality and favorable functional outcome. The safety outcomes were mortality, any hypoglycemia (symptomatic or asymptomatic), and symptomatic hypoglycemia.
Among 462 potentially eligible articles, nine studies with 1491 patients were included in the meta-analysis. There was no statistically significant difference in mortality between patients who were treated with intravenous insulin and controls (odds ratio: 1·16, 95% confidence interval: 0·89–1·49). Similarly, the rate of favorable functional outcome was not statistically different (odds ratio: 1·01, 95% confidence interval: 0·81–1·26). The rates of any hypoglycemia (odds ratio: 8·19, 95% confidence interval: 5·60–11·98) and of symptomatic hypoglycemia (odds ratio: 6·15, 95% confidence interval: 1·88–20·15) were higher in patients treated with intravenous insulin. There was no heterogeneity across the included trials in any of the outcomes studied.
This meta-analysis of randomized controlled trials does not support the use of intravenous insulin in hyperglycemic stroke patients to improve mortality or functional outcome. The risk of hypoglycemia is increased, however.